Please upgrade your browser.
Comprehensive molecular analysis is performed on 66 kidney chromophobe cases
Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
"CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has minimal expression in healthy tissues," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics.
Improve patient care by participating in The West Cancer Center Tumor Boards or start your own case discussions.
For most cancer patients and their doctors, the most important things to know about a tumor are where it arose in the body and how much it has grown.
Clear cell urothelial carcinoma is exceedingly rare, with only nine clinical cases described in the literature.
Brain metastasis occurs in 3.9-24% of patients with renal cell carcinoma (RCC), with an average interval from nephrectomy to brain metastasis of 1 to 3 years.
Sunitinib was administered for 9 months, which led to complete response (CR)
High body mass index (BMI) is associated with an elevated risk of various cancers in men and women, according to a new report.
Active surveillance in kidney cancer involves closely observing the tumor with periodic imaging studies rather than immediately proceeding to an invasive treatment.
A team of researchers and doctors in Singapore has developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients.
|Powered by NeonCRM|